Gilead Sciences, Inc. (GILD) Position Lessened by B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund

B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 47.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 17,053 shares of the biopharmaceutical company’s stock after selling 15,636 shares during the period. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Gilead Sciences were worth $1,208,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in GILD. Tompkins Financial Corp raised its stake in shares of Gilead Sciences by 4.4% in the 2nd quarter. Tompkins Financial Corp now owns 15,479 shares of the biopharmaceutical company’s stock valued at $1,096,000 after acquiring an additional 651 shares during the period. Benedict Financial Advisors Inc. raised its stake in shares of Gilead Sciences by 2.7% in the 2nd quarter. Benedict Financial Advisors Inc. now owns 25,473 shares of the biopharmaceutical company’s stock valued at $1,804,000 after acquiring an additional 673 shares during the period. Resource Management LLC raised its stake in shares of Gilead Sciences by 6.7% in the 2nd quarter. Resource Management LLC now owns 10,688 shares of the biopharmaceutical company’s stock valued at $757,000 after acquiring an additional 674 shares during the period. Jolley Asset Management LLC raised its stake in shares of Gilead Sciences by 1.3% in the 2nd quarter. Jolley Asset Management LLC now owns 54,746 shares of the biopharmaceutical company’s stock valued at $3,878,000 after acquiring an additional 678 shares during the period. Finally, Kornitzer Capital Management Inc. KS raised its stake in shares of Gilead Sciences by 0.4% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 174,000 shares of the biopharmaceutical company’s stock valued at $12,326,000 after acquiring an additional 710 shares during the period. 78.04% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on GILD shares. Piper Jaffray Companies started coverage on shares of Gilead Sciences in a research note on Wednesday, May 30th. They issued a “buy” rating and a $85.00 target price on the stock. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 6th. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, June 27th. Raymond James assumed coverage on shares of Gilead Sciences in a research note on Thursday, June 28th. They issued a “strong-buy” rating and a $93.00 target price on the stock. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a report on Wednesday, July 18th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and an average target price of $88.30.

GILD opened at $74.12 on Friday. The firm has a market cap of $93.63 billion, a P/E ratio of 8.66, a PEG ratio of -5.51 and a beta of 1.02. Gilead Sciences, Inc. has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a quick ratio of 2.92, a current ratio of 3.00 and a debt-to-equity ratio of 1.23.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.56 by $0.35. The company had revenue of $5.65 billion during the quarter, compared to analyst estimates of $5.20 billion. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The firm’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same period last year, the business earned $2.56 EPS. equities analysts forecast that Gilead Sciences, Inc. will post 6.56 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 27th. Shareholders of record on Friday, September 14th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 3.08%. The ex-dividend date is Thursday, September 13th. Gilead Sciences’s dividend payout ratio is currently 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $77.85, for a total transaction of $3,892,500.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at approximately $238,825,271.70. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 150,000 shares of company stock valued at $11,141,000. 1.30% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: Book Value Per Share – BVPS

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply